Uncategorized

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

Published

on

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version